engaging families, clinical colleagues, biotech and industry, in order to bring

tested products to market more quickly to benet mothers and babies.

4 slots of 15/30 minutes plus discussion will be available for industries to

discuss about their planned multicentre/international studies. These will provide

opportunity to explain the scientic rationale, evidence to date, discuss the

intended methodological approach, and obtain views and perspectives from

delegates. The intention is to facilitate the development of studies that are

acceptable to families and clinicians, meet regulatory requirements, and are

feasible and cost-effective.